12 January 2022 - Drugs for orphan diseases should also go through a regular benefit assessment procedure when they enter the ...
3 January 2022 - Janssen applied for a new early benefit assessment due to new scientific findings. ...
1 December 2021 - Those affected develop fewer relapses than if they wait and see. ...
1 December 2021 - Women should expect more serious adverse effects than men. ...
1 December 2021 - In an open-access publication in the Journal of European CME, two authors from IQWiG argue that ...
24 November 2021 - Germany's prospective three-party government plans to cut prices retroactively for recently-launched prescription drugs to keep health ...
4 November 2021 - The Federal Joint Committee (G-BA) today assessed the additional benefit of two active ingredients against very rare, ...
1 October 2021 - For the first time, a pure antibody combination has been approved as a first-line therapy for ...
1 October 2021 - Hint of considerable additional benefit if, after complete tumour resection, adjuvant platinum-based chemotherapy has already been ...
16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated ...
16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...
15 September 2021 - Third new area of application/those affected still live a good year on average - and thus ...
23 August 2021 - The IQWiG has presented the draft for the next version of its General Methods. ...
16 August 2021 - With risdiplam there is a hint of an added benefit for spinal muscular atrophy type 1, ...
16 August 2021 - The active ingredient has exceeded the sales limit for the simplified orphan drug assessment. There are no ...